1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial

Detalles Bibliográficos
Autores principales: Giaccone, G., Felip, E., Cobo, M., Campelo, R. Garcia, DENIS, F., Quoix, E., Madroszyk, A., Debieuvre, D., Hilgers, W., Moran, T., Galetta, D., Romano, G.D., Cappuzzo, F., Robinet, G., Masson, P., Viteri, S., Peled, N., Costantini, D., Dziadziuszko, R., Besse, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506388/
http://dx.doi.org/10.1016/j.annonc.2020.08.1574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506388/
http://dx.doi.org/10.1016/j.annonc.2020.08.1574

Ejemplares similares